OncoTherapy Science, Inc. (4564.T)
JPY 25.0
(8.7%)
JPY 25.0
(8.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.28 Billion JPY | -15.15% |
| 2022 | -1.11 Billion JPY | 56.5% |
| 2021 | -2.57 Billion JPY | -64.67% |
| 2020 | -1.56 Billion JPY | 30.24% |
| 2019 | -2.23 Billion JPY | 23.73% |
| 2018 | -2.93 Billion JPY | -2.94% |
| 2017 | -2.85 Billion JPY | 5.03% |
| 2016 | -3 Billion JPY | -7.65% |
| 2015 | -2.78 Billion JPY | -108.92% |
| 2014 | -1.33 Billion JPY | 63.69% |
| 2013 | -3.67 Billion JPY | -233.27% |
| 2012 | -1.1 Billion JPY | -251.76% |
| 2011 | 726.96 Million JPY | 28.27% |
| 2010 | 566.75 Million JPY | 11.09% |
| 2009 | 510.15 Million JPY | 244.12% |
| 2008 | 148.24 Million JPY | 173.36% |
| 2007 | -202.07 Million JPY | 84.73% |
| 2006 | -1.32 Billion JPY | -151.73% |
| 2005 | -525.7 Million JPY | -3122.65% |
| 2004 | 17.39 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -302 Million JPY | -0.4% |
| 2023 Q3 | -276.66 Million JPY | 10.8% |
| 2023 Q2 | -310.17 Million JPY | 22.55% |
| 2023 Q1 | -400.48 Million JPY | -94.93% |
| 2023 Q4 | -300.8 Million JPY | -8.73% |
| 2023 FY | -1.28 Billion JPY | -15.15% |
| 2022 Q3 | -299.4 Million JPY | 10.89% |
| 2022 Q4 | -205.44 Million JPY | 31.38% |
| 2022 FY | -1.11 Billion JPY | 56.5% |
| 2022 Q2 | -335.99 Million JPY | -20.95% |
| 2022 Q1 | -277.79 Million JPY | 35.74% |
| 2021 Q4 | -432.33 Million JPY | 52.46% |
| 2021 Q3 | -909.48 Million JPY | -30.9% |
| 2021 FY | -2.57 Billion JPY | -64.67% |
| 2021 Q2 | -694.79 Million JPY | -29.89% |
| 2021 Q1 | -534.92 Million JPY | -41.19% |
| 2020 Q3 | -426.1 Million JPY | 2.65% |
| 2020 FY | -1.56 Billion JPY | 30.24% |
| 2020 Q4 | -378.86 Million JPY | 11.09% |
| 2020 Q1 | -318.97 Million JPY | 31.07% |
| 2020 Q2 | -437.69 Million JPY | -37.22% |
| 2019 Q2 | -611.34 Million JPY | 5.3% |
| 2019 Q3 | -518.92 Million JPY | 15.12% |
| 2019 Q1 | -645.57 Million JPY | 37.95% |
| 2019 FY | -2.23 Billion JPY | 23.73% |
| 2019 Q4 | -462.72 Million JPY | 10.83% |
| 2018 Q2 | -895.12 Million JPY | -38.33% |
| 2018 FY | -2.93 Billion JPY | -2.94% |
| 2018 Q4 | -1.04 Billion JPY | -195.33% |
| 2018 Q1 | -647.1 Million JPY | 8.13% |
| 2018 Q3 | -352.29 Million JPY | 60.64% |
| 2017 Q1 | -568.24 Million JPY | 29.24% |
| 2017 FY | -2.85 Billion JPY | 5.03% |
| 2017 Q4 | -704.34 Million JPY | 9.65% |
| 2017 Q3 | -779.59 Million JPY | 2.42% |
| 2017 Q2 | -798.91 Million JPY | -40.59% |
| 2016 FY | -3 Billion JPY | -7.65% |
| 2016 Q2 | -732.44 Million JPY | 4.23% |
| 2016 Q4 | -803.05 Million JPY | -14.43% |
| 2016 Q3 | -701.76 Million JPY | 4.19% |
| 2016 Q1 | -764.79 Million JPY | -15.02% |
| 2015 Q4 | -664.91 Million JPY | 15.8% |
| 2015 FY | -2.78 Billion JPY | -108.92% |
| 2015 Q1 | -540.12 Million JPY | -58.42% |
| 2015 Q2 | -794.08 Million JPY | -47.02% |
| 2015 Q3 | -789.69 Million JPY | 0.55% |
| 2014 Q1 | -168.23 Million JPY | 78.33% |
| 2014 FY | -1.33 Billion JPY | 63.69% |
| 2014 Q2 | -579.49 Million JPY | -244.45% |
| 2014 Q3 | -246.2 Million JPY | 57.51% |
| 2014 Q4 | -340.95 Million JPY | -38.49% |
| 2013 Q1 | -1.05 Billion JPY | -321.38% |
| 2013 Q3 | -885.8 Million JPY | 7.99% |
| 2013 FY | -3.67 Billion JPY | -233.27% |
| 2013 Q4 | -776.2 Million JPY | 12.37% |
| 2013 Q2 | -962.67 Million JPY | 8.49% |
| 2012 Q2 | -374.09 Million JPY | 49.8% |
| 2012 Q1 | -745.26 Million JPY | -125.68% |
| 2012 FY | -1.1 Billion JPY | -251.76% |
| 2012 Q3 | -459.02 Million JPY | -22.7% |
| 2012 Q4 | 475.17 Million JPY | 203.52% |
| 2011 Q4 | 2.9 Billion JPY | 535.17% |
| 2011 Q1 | -1.01 Billion JPY | -309.15% |
| 2011 Q2 | -494.26 Million JPY | 51.24% |
| 2011 Q3 | -666.79 Million JPY | -34.91% |
| 2011 FY | 726.96 Million JPY | 28.27% |
| 2010 Q1 | -841.29 Million JPY | -151.33% |
| 2010 Q2 | 342.75 Million JPY | 140.74% |
| 2010 Q3 | 580.65 Million JPY | 69.41% |
| 2010 Q4 | 484.65 Million JPY | -16.53% |
| 2010 FY | 566.75 Million JPY | 11.09% |
| 2009 Q1 | -758.14 Million JPY | -139.75% |
| 2009 FY | 510.15 Million JPY | 244.12% |
| 2009 Q4 | 1.63 Billion JPY | 1545.71% |
| 2009 Q3 | 99.58 Million JPY | 121.18% |
| 2009 Q2 | -470.23 Million JPY | 37.98% |
| 2008 FY | 148.24 Million JPY | 173.36% |
| 2008 Q3 | -481.84 Million JPY | 0.0% |
| 2008 Q4 | 1.9 Billion JPY | 495.86% |
| 2007 FY | -202.07 Million JPY | 84.73% |
| 2006 FY | -1.32 Billion JPY | -151.73% |
| 2005 FY | -525.7 Million JPY | -3122.65% |
| 2004 FY | 17.39 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 435.453% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -144.468% |
| GNI Group Ltd. | 8.09 Billion JPY | 115.914% |
| Linical Co., Ltd. | 338.26 Million JPY | 480.806% |
| Trans Genic Inc. | 4.08 Million JPY | 31633.366% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 10.418% |
| Soiken Holdings Inc. | -662.2 Million JPY | -94.523% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 1032.386% |
| AnGes, Inc. | -7.43 Billion JPY | 82.681% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 82.092% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 789.973% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -65.145% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -11.731% |
| CanBas Co., Ltd. | -1.2 Billion JPY | -6.546% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -58.557% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -297.989% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | -5.584% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 9.419% |
| PeptiDream Inc. | 3.03 Billion JPY | 142.431% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 33.55% |
| Ribomic Inc. | -1.02 Billion JPY | -25.766% |
| SanBio Company Limited | -2.64 Billion JPY | 51.281% |
| Healios K.K. | -3.82 Billion JPY | 66.306% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -10.278% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 13.525% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 9.882% |
| StemRIM | -2.02 Billion JPY | 36.294% |
| CellSource Co., Ltd. | 923.14 Million JPY | 239.538% |
| FunPep Company Limited | -933.41 Million JPY | -38.003% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -50.809% |
| Stella Pharma Corporation | -763.74 Million JPY | -68.66% |
| TMS Co., Ltd. | -960.04 Million JPY | -34.175% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -13.993% |
| Cuorips Inc. | -632.18 Million JPY | -103.76% |
| K Pharma,Inc. | 260.33 Million JPY | 594.81% |
| Takara Bio Inc. | 1.48 Billion JPY | 187.036% |
| ReproCELL Incorporated | -31.41 Million JPY | -4000.392% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 4983.38% |
| StemCell Institute Inc. | 310.98 Million JPY | 514.218% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 999.732% |
| CellSeed Inc. | -846.53 Million JPY | -52.166% |